Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
| Autor: | Miguel Ángel Mendoza-Torres, Belinda Guzmán-Flores, Elain Rivera-García, María Del Carmen Baxin Domínguez, Francisca Sosa-Jurado, Paulina Cortés-Hernández, Julio Reyes-Leyva, José Manuel Coronel Espinoza, Verónica Vallejo-Ruiz, Daniel Meléndez-Mena, Iván Galindo-Santiago, Laura Sánchez-Reza, Virginia Sedeño-Monge, Gerardo Santos-López, Víctor Hugo García y García, Ygnacio Martínez-Laguna, Juan Carlos Flores-Alonso |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
APRI index
medicine.medical_specialty Drugs and Devices Sustained viral response Sofosbuvir Child-Pugh-Score Gastroenterology and Hepatology Gastroenterology General Biochemistry Genetics and Molecular Biology Direct acting antivirals chemistry.chemical_compound Pegylated interferon Internal medicine Virology medicine Dasabuvir business.industry General Neuroscience Ribavirin virus diseases General Medicine Hepatitis C medicine.disease Ombitasvir Infectious Diseases chemistry Paritaprevir FIB-4 Medicine Ritonavir General Agricultural and Biological Sciences business medicine.drug |
| Zdroj: | PeerJ PeerJ, Vol 9, p e12051 (2021) |
| ISSN: | 2167-8359 |
| Popis: | Background Direct Acting Antivirals (DAAs) represent a large improvement in the treatment of chronic hepatitis C, resulting in Methods A descriptive, ambispective, longitudinal study was conducted. A cohort of 261 adult patients received PegIFNα2a+RBV therapy before 2014; 167 (64%) did not respond, 83 of these were subsequently treated with SOF/LDV ± RBV or OBV/PTV/r/DSV ± RBV. Child-Pugh-Score (CPS), Fibrosis-4 (FIB-4), and AST to Platelet Ratio Index (APRI) were evaluated before and after treatment. Results SVR with PegIFNα2a+RBV was 36%, and 97.5% with DAAs. CPS, FIB-4 and APRI improved significantly after DAA treatment, mainly because of liver transaminase reduction. Conclusions DAA treatment showed excellent SVR rates in Mexican patients who had not responded to PegIFNα2a+RBV therapy. Improvement in CPS, FIB-4 and APRI without improvement in fibrosis was observed in cirrhotic and non-cirrhotic patients, as well as considerable reduction in liver transaminases, which suggests a reduction in hepatic necroinflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|